• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Utilization of Subcutaneous Cardioverter-Defibrillator in Poland and Europe-Comparison of the Results of Multi-Center Registries.波兰和欧洲皮下植入式心脏除颤器的应用——多中心注册研究结果的比较。
Int J Environ Res Public Health. 2021 Jul 5;18(13):7178. doi: 10.3390/ijerph18137178.
2
Factors determining the choice between subcutaneous or transvenous implantable cardioverter-defibrillators in Poland in comparison with other European countries: a sub-study of the European Heart Rhythm Association prospective survey.波兰与其他欧洲国家相比,决定皮下或经静脉植入式心脏复律除颤器选择的因素:欧洲心律协会前瞻性调查的子研究。
Kardiol Pol. 2018;76(11):1507-1515. doi: 10.5603/KP.a2018.0155. Epub 2018 Aug 9.
3
Subcutaneous implantable cardioverter-defibrillator therapy in Poland: Results of the Polish S-ICD Registry.波兰皮下植入式心律转复除颤器治疗:波兰 S-ICD 登记研究结果。
Kardiol Pol. 2023;81(5):455-462. doi: 10.33963/KP.a2023.0046. Epub 2023 Mar 5.
4
Peri-procedural routines, implantation techniques, and procedure-related complications in patients undergoing implantation of subcutaneous or transvenous automatic cardioverter-defibrillators: results of the European Snapshot Survey on S-ICD Implantation (ESSS-SICDI).接受皮下或经静脉自动心脏除颤器植入术患者的围手术期常规、植入技术和与手术相关的并发症:欧洲皮下 ICD 植入术快照调查(ESSS-SICDI)的结果。
Europace. 2018 Jul 1;20(7):1218-1224. doi: 10.1093/europace/euy092.
5
Factors influencing the use of subcutaneous or transvenous implantable cardioverter-defibrillators: results of the European Heart Rhythm Association prospective survey.影响皮下或经静脉植入式心脏复律除颤器使用的因素:欧洲心律协会前瞻性调查结果。
Europace. 2018 May 1;20(5):887-892. doi: 10.1093/europace/euy009.
6
A survey study of the use of a subcutaneous implantable cardioverter-defibrillator in various clinical scenarios by expert electrophysiologists in Poland.波兰专家电生理学家在各种临床情况下使用皮下植入式心律转复除颤器的调查研究。
Cardiol J. 2023;30(2):214-220. doi: 10.5603/CJ.a2022.0073. Epub 2022 Aug 17.
7
Initial experience with the subcutaneous implantable cardioverter-defibrillator with the real costs of hospitalization analysis in a single Polish center.波兰单一中心皮下植入式心律转复除颤器的初步经验及住院实际费用分析
Cardiol J. 2019;26(4):360-367. doi: 10.5603/CJ.a2018.0024. Epub 2018 Apr 3.
8
Specific indications and clinical outcome in patients with subcutaneous implantable cardioverter-defibrillator (ICD) - A nationwide multicentre registry.皮下植入式心律转复除颤器(ICD)患者的具体适应证和临床结局-全国多中心注册研究。
Eur J Intern Med. 2018 Feb;48:64-68. doi: 10.1016/j.ejim.2017.09.038. Epub 2017 Oct 1.
9
Use and outcomes of subcutaneous implantable cardioverter-defibrillator (ICD) after transvenous ICD extraction: An analysis of current clinical practice and a comparison with transvenous ICD reimplantation.经静脉植入式心脏复律除颤器(ICD)取出后皮下植入式 ICD 的使用和结局:对当前临床实践的分析及与经静脉 ICD 再植入的比较。
Heart Rhythm. 2019 Apr;16(4):564-571. doi: 10.1016/j.hrthm.2018.10.026. Epub 2018 Oct 24.
10
Long-Term Experience With the Subcutaneous Implantable Cardioverter-Defibrillator in Teenagers and Young Adults.青少年和年轻成人中皮下植入式心脏复律除颤器的长期经验
JACC Clin Electrophysiol. 2017 Dec 26;3(13):1499-1506. doi: 10.1016/j.jacep.2017.08.017. Epub 2017 Nov 6.

引用本文的文献

1
Application of Novel Technologies in Cardiac Electrotherapy to Prevent Complications.新型技术在心脏电治疗中预防并发症的应用。
Diagnostics (Basel). 2023 Apr 28;13(9):1584. doi: 10.3390/diagnostics13091584.
2
A survey study of the use of a subcutaneous implantable cardioverter-defibrillator in various clinical scenarios by expert electrophysiologists in Poland.波兰专家电生理学家在各种临床情况下使用皮下植入式心律转复除颤器的调查研究。
Cardiol J. 2023;30(2):214-220. doi: 10.5603/CJ.a2022.0073. Epub 2022 Aug 17.

本文引用的文献

1
Subcutaneous versus transvenous implantable defibrillator: An updated meta-analysis.皮下与经静脉植入式除颤器:一项更新的荟萃分析。
Heart Rhythm. 2021 Mar;18(3):382-391. doi: 10.1016/j.hrthm.2020.11.013. Epub 2020 Nov 16.
2
Subcutaneous or Transvenous Defibrillator Therapy.皮下或经静脉除颤器治疗。
N Engl J Med. 2020 Aug 6;383(6):526-536. doi: 10.1056/NEJMoa1915932.
3
Electrotherapy and electrophysiology procedures during the coronavirus disease 2019 pandemic: an opinion of the Heart Rhythm Section of the Polish Cardiac Society (with an update).2019冠状病毒病大流行期间的电疗法和电生理程序:波兰心脏病学会心律分会的意见(附更新内容)
Kardiol Pol. 2020 May 25;78(5):488-492. doi: 10.33963/KP.15338. Epub 2020 May 5.
4
Factors determining the choice between subcutaneous or transvenous implantable cardioverter-defibrillators in Poland in comparison with other European countries: a sub-study of the European Heart Rhythm Association prospective survey.波兰与其他欧洲国家相比,决定皮下或经静脉植入式心脏复律除颤器选择的因素:欧洲心律协会前瞻性调查的子研究。
Kardiol Pol. 2018;76(11):1507-1515. doi: 10.5603/KP.a2018.0155. Epub 2018 Aug 9.
5
Factors influencing the use of subcutaneous or transvenous implantable cardioverter-defibrillators: results of the European Heart Rhythm Association prospective survey.影响皮下或经静脉植入式心脏复律除颤器使用的因素:欧洲心律协会前瞻性调查结果。
Europace. 2018 May 1;20(5):887-892. doi: 10.1093/europace/euy009.
6
2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: Executive summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society.2017年美国心脏协会/美国心脏病学会/心律学会室性心律失常患者管理和心脏性猝死预防指南:执行摘要:美国心脏病学会/美国心脏协会临床实践指南工作组和心律学会报告
Heart Rhythm. 2018 Oct;15(10):e190-e252. doi: 10.1016/j.hrthm.2017.10.035. Epub 2017 Oct 30.
7
Subcutaneous implantable cardioverter-defibrillator (S-ICD) for secondary prevention of sudden cardiac death.皮下植入式心律转复除颤器(S-ICD)用于心脏性猝死的二级预防。
Arch Med Sci. 2016 Oct 1;12(5):1179-1180. doi: 10.5114/aoms.2016.61921. Epub 2016 Aug 25.
8
2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC). Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC).2015年欧洲心脏病学会(ESC)室性心律失常患者管理和心脏性猝死预防指南:欧洲心脏病学会(ESC)室性心律失常患者管理和心脏性猝死预防特别工作组。认可机构:欧洲儿科和先天性心脏病协会(AEPC)。
Eur Heart J. 2015 Nov 1;36(41):2793-2867. doi: 10.1093/eurheartj/ehv316. Epub 2015 Aug 29.
9
A subcutaneous implantable cardioverter-defibrillator - the first implantation in Poland.
Kardiol Pol. 2015;73(1):62. doi: 10.5603/KP.2015.0010.
10
Worldwide experience with a totally subcutaneous implantable defibrillator: early results from the EFFORTLESS S-ICD Registry.全球完全皮下植入式除颤器的经验:来自EFFORTLESS S-ICD注册研究的早期结果。
Eur Heart J. 2014 Jul 1;35(25):1657-65. doi: 10.1093/eurheartj/ehu112. Epub 2014 Mar 26.

波兰和欧洲皮下植入式心脏除颤器的应用——多中心注册研究结果的比较。

Utilization of Subcutaneous Cardioverter-Defibrillator in Poland and Europe-Comparison of the Results of Multi-Center Registries.

机构信息

Department of Cardiology and Electrotherapy, Medical University of Gdansk, 80-210 Gdansk, Poland.

Medical College, University of Rzeszow, 35-959 Rzeszow, Poland.

出版信息

Int J Environ Res Public Health. 2021 Jul 5;18(13):7178. doi: 10.3390/ijerph18137178.

DOI:10.3390/ijerph18137178
PMID:34281115
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8297309/
Abstract

The implantation of a subcutaneous cardioverter-defibrillator (S-ICD) may be used instead of a traditional transvenous system to prevent sudden cardiac death. Our aim was to compare the characteristics of S-ICD patients from the multi-center registry of S-ICD implantations in Poland with the published results of the European Snapshot Survey on S-ICD Implantation (ESSS-SICDI). We compared data of 137 Polish S-ICD patients with 68 patients from the ESSS-SICDI registry. The groups did not differ significantly in terms of sex, prevalence of ischemic cardiomyopathy, concomitant diseases, and the rate of primary prevention indication. Polish patients had more advanced heart failure (New York Heart Association (NYHA) class III: 11.7% vs. 2.9%, NYHA II: 48.9% vs. 29.4%, NYHA I: 39.4% vs. 67.7%, < 0.05 each). Young age (75.9% vs. 50%, < 0.05) and no vascular access (7.3% vs. 0%, < 0.05) were more often indications for S-ICD. The percentage of patients after transvenous system removal due to infections was significantly higher in the Polish group (11% vs. 1.5%, < 0.05). In the European population, S-ICD was more frequently chosen because of patients' active lifestyle and patients' preference (both 10.3% vs. 0%, < 0.05). Our analysis shows that in Poland, compared to other European countries, subcutaneous cardioverters-defibrillators are being implanted in patients at a more advanced stage of chronic heart failure. The most frequent reason for choosing a subcutaneous system instead of a transvenous ICD is the young age of a patient.

摘要

皮下植入式心律转复除颤器(S-ICD)可替代传统的经静脉系统,用于预防心源性猝死。我们旨在比较波兰多中心 S-ICD 植入登记处的 S-ICD 患者特征与已发表的欧洲 S-ICD 植入Snapshot 调查(ESSS-SICDI)的结果。我们比较了 137 例波兰 S-ICD 患者和 ESSS-SICDI 登记处的 68 例患者的数据。两组在性别、缺血性心肌病患病率、合并症和一级预防指征发生率方面无显著差异。波兰患者心力衰竭更严重(纽约心脏协会(NYHA)心功能分级 III 级:11.7% vs. 2.9%,NYHA 心功能分级 II 级:48.9% vs. 29.4%,NYHA 心功能分级 I 级:39.4% vs. 67.7%,均<0.05)。年轻(75.9% vs. 50%,<0.05)和无血管通路(7.3% vs. 0%,<0.05)更常作为 S-ICD 的指征。因感染而移除经静脉系统的患者在波兰组中比例显著更高(11% vs. 1.5%,<0.05)。在欧洲人群中,S-ICD 因患者的积极生活方式和患者偏好而更常被选择(均为 10.3% vs. 0%,<0.05)。我们的分析表明,与其他欧洲国家相比,波兰在慢性心力衰竭更晚期的患者中植入皮下除颤器。选择皮下系统而非经静脉 ICD 的最常见原因是患者较年轻。